Skip to Content

Nationwide Study Shows BNT162b2 mRNA Vaccine Is Effective

WEDNESDAY, Feb. 24, 2021 -- The BNT162b2 mRNA vaccine is effective for COVID-19-related outcomes, including hospitalization, severe illness, and death, in a nationwide, mass vaccination setting, according to a study published online Feb. 24 in the New England Journal of Medicine.

Noa Dagan, M.D., from Clalit Health Services in Tel Aviv, Israel, and colleagues examined the effectiveness of the BNT162b2 mRNA vaccine using data from Israel's largest health care organization. All 596,618 persons who were newly vaccinated during Dec. 20, 2020, to Feb. 1, 2021, were matched to 596,618 unvaccinated controls. Study outcomes included documented infection with severe acute respiratory syndrome coronavirus 2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness, and death.

The researchers found that at 14 through 20 days after the first dose and at seven or more days after the second dose, the estimated vaccine effectiveness was 46 and 92 percent, respectively, for documented infection; 57 and 94 percent for symptomatic COVID-19; 74 and 87 percent for hospitalization; and 62 and 92 percent for severe disease. For preventing death from COVID-19, the estimated effectiveness was 72 percent for days 14 through 20 after the first dose. Across age groups, the estimated effectiveness was consistent for documented infection and symptomatic COVID-19 in specific subpopulations, with potentially slightly lower effectiveness in those with multiple coexisting conditions.

"This study estimates a high effectiveness of the BNT162b2 vaccine for preventing symptomatic COVID-19 in a noncontrolled setting," the authors write. "These results strengthen the expectation that newly approved vaccines can help to mitigate the profound global effects of the COVID-19 pandemic."

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

SARS-CoV-2 Cardiac Involvement Low in Collegiate Athletes

TUESDAY, April 20, 2021 -- For U.S. collegiate athletes, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a low prevalence of cardiac...

Total Vaccines, Measles Vaccines Down for Children During Pandemic

TUESDAY, April 20, 2021 -- During the pandemic, there has been a decrease in total and measles-containing vaccines in all children, according to a study published online April 15...

Some Supplements May Lower Risk for SARS-CoV-2 Positivity

TUESDAY, April 20, 2021 -- The use of probiotics, omega-3 fatty acids, multivitamins, and vitamin D supplements is associated with a reduction in the risk for testing positive for...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.